These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36479595)

  • 1. Circulating selenoprotein P levels predict glucose-lowering and insulinotropic effects of metformin, but not alogliptin: A post-hoc analysis.
    Takeshita Y; Tanaka T; Takayama H; Kita Y; Goto H; Nakano Y; Saito Y; Takamura T
    J Diabetes Investig; 2023 Feb; 14(2):230-235. PubMed ID: 36479595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of metformin and alogliptin on body composition in people with type 2 diabetes.
    Takeshita Y; Kita Y; Kato KI; Kanamori T; Misu H; Kaneko S; Takamura T
    J Diabetes Investig; 2019 May; 10(3):723-730. PubMed ID: 30156056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin suppresses expression of the selenoprotein P gene via an AMP-activated kinase (AMPK)/FoxO3a pathway in H4IIEC3 hepatocytes.
    Takayama H; Misu H; Iwama H; Chikamoto K; Saito Y; Murao K; Teraguchi A; Lan F; Kikuchi A; Saito R; Tajima N; Shirasaki T; Matsugo S; Miyamoto K; Kaneko S; Takamura T
    J Biol Chem; 2014 Jan; 289(1):335-45. PubMed ID: 24257750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
    Del Prato S; Camisasca R; Wilson C; Fleck P
    Diabetes Obes Metab; 2014 Dec; 16(12):1239-46. PubMed ID: 25132212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of eicosapentaenoic acid on serum levels of selenoprotein P and organ-specific insulin sensitivity in humans with dyslipidemia and type 2 diabetes.
    Takeshita Y; Teramura C; Kamoshita K; Takayama H; Nakagawa H; Enyama Y; Ishii KA; Tanaka T; Goto H; Nakano Y; Osada S; Tanaka Y; Tokuyama K; Takamura T
    J Diabetes Investig; 2022 Mar; 13(3):532-542. PubMed ID: 34670012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
    Nauck MA; Ellis GC; Fleck PR; Wilson CA; Mekki Q;
    Int J Clin Pract; 2009 Jan; 63(1):46-55. PubMed ID: 19125992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
    Jarvis CI; Cabrera A; Charron D
    Ann Pharmacother; 2013 Nov; 47(11):1532-9. PubMed ID: 24285765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes.
    Kaku K; Sumino S; Katou M; Nishiyama Y; Kinugawa Y
    Diabetes Obes Metab; 2017 Mar; 19(3):463-467. PubMed ID: 27891757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selenoprotein P as a diabetes-associated hepatokine that impairs angiogenesis by inducing VEGF resistance in vascular endothelial cells.
    Ishikura K; Misu H; Kumazaki M; Takayama H; Matsuzawa-Nagata N; Tajima N; Chikamoto K; Lan F; Ando H; Ota T; Sakurai M; Takeshita Y; Kato K; Fujimura A; Miyamoto K; Saito Y; Kameo S; Okamoto Y; Takuwa Y; Takahashi K; Kidoya H; Takakura N; Kaneko S; Takamura T
    Diabetologia; 2014 Sep; 57(9):1968-76. PubMed ID: 24989996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
    Seino Y; Miyata Y; Hiroi S; Hirayama M; Kaku K
    Diabetes Obes Metab; 2012 Oct; 14(10):927-36. PubMed ID: 22583697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.
    White WB; Heller SR; Cannon CP; Howitt H; Khunti K; Bergenstal RM;
    Am J Med; 2018 Jul; 131(7):813-819.e5. PubMed ID: 29581078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Pratley RE; Reusch JE; Fleck PR; Wilson CA; Mekki Q;
    Curr Med Res Opin; 2009 Oct; 25(10):2361-71. PubMed ID: 19650752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
    Pan C; Han P; Ji Q; Li C; Lu J; Yang J; Li W; Zeng J; Hsieh AT; Chan J
    J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different daily glycemic profiles after switching from once-daily alogliptin plus twice-daily metformin to their once-daily fixed-dose combination in Japanese type 2 diabetic patients.
    Takahara M; Shiraiwa T; Katakami N; Maeno Y; Yamamoto K; Shiraiwa Y; Yoshida Y; Matsuoka TA; Shimomura I
    Endocr J; 2019 Jan; 66(1):11-17. PubMed ID: 30305482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
    Pratley RE; Kipnes MS; Fleck PR; Wilson C; Mekki Q;
    Diabetes Obes Metab; 2009 Feb; 11(2):167-76. PubMed ID: 19125778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study.
    Kim JM; Kim SS; Kim JH; Kim MK; Kim TN; Lee SH; Lee CW; Park JY; Kim ES; Lee KJ; Choi YS; Kim DK; Kim IJ
    Diabetes Metab J; 2020 Feb; 44(1):67-77. PubMed ID: 31339011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety of alogliptin in treatment of type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial in mainland China].
    Pan C; Li W; Zeng J; Li C; Yang J; Ji Q; Lu J; Lyu X; Li X; Qu S; Xu X; Xue Y; Li L; Jiang Z; Zheng B; Bu R; Han P; Liu Y; Liu J; Peng Y; Liu X; Liu Z; Yan L; Lei M; Li X; Song Q; Shi B; Gu W; Li Z
    Zhonghua Nei Ke Za Zhi; 2015 Nov; 54(11):949-53. PubMed ID: 26759214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
    Ndefo UA; Okoli O; Erowele G
    Am J Health Syst Pharm; 2014 Jan; 71(2):103-9. PubMed ID: 24375601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
    Pratley RE; McCall T; Fleck PR; Wilson CA; Mekki Q
    J Am Geriatr Soc; 2009 Nov; 57(11):2011-9. PubMed ID: 19793357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.